In the latest trading session, Novavax (NVAX) closed at $4.33, marking a +0.93% move from the previous day. This move outpaced the S&P 500's daily loss of 1.57%. Elsewhere, the Dow saw a downswing of ...

Novavax's NVAX short percent of float has fallen 8.76% since its last report. The company recently reported that it has 43.91 million shares sold short, which is 36.57% of all regular shares that are ...

Data presented at ESCMID Global 2024 highlights the efficacy of vaccines against malaria, Streptococcus pneumoniae and more.

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

In a new regulatory filing, Shah Capital, which owns 9.3 million shares of Novavax representing a 6.66% stake in the company, ...

NEW YORK, NY / ACCESSWIRE / April 25, 2024 / Levi & Korsinsky informs shareholders that a settlement has been reached in the pending class ...

The new private COVID-19 vaccine, manufactured by Novavax and delivered for the first time in the UK by an independent ...

I f there is one thing Bluebird Bio (NASDAQ: BLUE) and Novavax (NASDAQ: NVAX) have in common, other than their belonging to ...

Also, subunit vaccine technology, which uses purified protein antigens derived from the target pathogen, is being used to ...

Shah Capital, a major shareholder in Novavax, urges board shake-up citing underperformance and failure to maximize ...

A team of Montana researchers is playing a key role in the development of a more effective vaccine against tuberculosis, an ...

April 15 (Reuters) - A top shareholder of COVID-19 vaccine maker Novavax (NVAX.O) , opens new tab on Monday said the company has been badly mismanaged and nominated two candidates to serve on ...